NanOlogy Welcomes Dr. John M. Goldberg as Chief Medical Officer to Drive Oncology Drug Development

NanOlogy Appoints Dr. John M. Goldberg as Chief Medical Officer

In a significant development for the oncology field, NanOlogy, LLC, a clinical-stage company focused on cancer treatments, has officially appointed Dr. John M. Goldberg, MD, as its fractional Chief Medical Officer (CMO). This strategic move aims to expedite the advancement of NanOlogy’s specialized drug portfolio, particularly its Large Surface Area Microparticle (LSAM) investigational drugs that are currently in the pipeline. Notably, efforts will be directed towards a program targeting Diffuse Intrinsic Pontine Glioma (DIPG), a challenging form of pediatric brain cancer with few available treatment options.

Dr. Goldberg comes with an impressive resume featuring over 20 years of extensive experience in various phases of drug development—from early research to late-phase clinical trials. He has held pivotal roles as CMO in previous organizations, including Rafael Holding, Inc., and Oncorus, Inc., focusing on drug therapies aimed at treating various types of cancers. His background includes senior positions in prominent companies like H3 Biomedicine Inc. and Agenus, Inc. In addition, Dr. Goldberg has contributed to academia, serving as a Lecturer at Harvard Medical School and an Associate Professor at the University of Miami Miller School of Medicine.

David Arthur, CEO of NanOlogy, stated, "As we progress our DIPG program toward initiating a clinical trial in late 2026, John will play a critical role in our development strategy and execution. His wide-ranging expertise in both drug development and business strategy is set to enhance our capabilities in advancing these essential treatments."

Expressing his enthusiasm for the role, Dr. Goldberg remarked, "I am impressed by NanOlogy's trajectory and believe that my background, particularly in the development of intratumoral therapies, uniquely positions me to contribute to the company’s future success. My immediate goals include advancing the DIPG program and identifying the best clinical pathways for our adult solid tumor investigational drugs. I look forward to working together to drive significant progress that can benefit cancer patients."

About NanOlogy

NanOlogy, LLC specializes in creating innovative oncological treatments designed for solid tumors. Utilizing cutting-edge technology, specifically the CritiTech Particle Engineering Solutions’ Purcision™ platform, the company produces LSAMs—microparticles designed for direct local delivery that manage to bypass issues related to systemic toxicity while enhancing tumor bioavailability. This innovative approach has shown promise across various solid tumors, including pancreatic, lung, bladder, and ovarian cancers among others.

To date, NanOlogy has successfully navigated the development of investigational drugs within multiple cancer types and is backed by a robust intellectual property portfolio, featuring over 100 issued patents worldwide. With its commitment to delivering safe and effective treatment solutions, NanOlogy is poised to make significant contributions to the landscape of cancer care, particularly with its focus on optimizing local tumor treatments using advanced delivery mechanisms.

As the company looks ahead, the appointment of Dr. Goldberg adds a wealth of impressive talent and expertise, essential to navigating the complexities of oncology drug development and fostering innovative solutions for patients in need.